---
document_datetime: 2025-01-07 15:09:31
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/rybelsus-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: rybelsus-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.5862981
conversion_datetime: 2025-12-24 00:35:36.285319
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Rybelsus

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                |
|----------------------|-----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0042               | Renewal of the marketing authorisation. | 19/09/2024                          | 22/11/2024                                  | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Rybelsus in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IG/1792   | - Changes (Safety/Efficacy) of Human and Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/10/2024   |            | SmPC and PL            | C.I.z Veterinary   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|--------------------|
| II/0041   | Update of section 4.6 of the SmPC in order to update information on breast-feeding based on final results from study NN9924-4669. This was an open-label, single-armed, multiple-dose, multi-centre study evaluating the semaglutide and SNAC concentrations in breast milk from healthy lactating women dosed once daily with oral semaglutide for 10 days (3 mg for 5 days followed by 7 mg for 5 days). The primary endpoints were evaluated during a 24 hours pharmacokinetic (PK) sampling period after the 10th dose. The package leaflet is updated accordingly. The RMP version 9.1 has also been submitted C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 03/10/2024   |            | SmPC and PL            | data               |
| X/0039    | Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 25/07/2024   | 19/09/2024 | SmPC, Labelling and PL |                    |
| X/0038    | Annex I_2.(a) Change of bioavailability Annex I_2.(c) Change or addition of a new strength/potency                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/05/2024   | 01/08/2024 | SmPC, Labelling and PL |                    |
| IB/0040/G | This was an application for a group of variations. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 21/06/2024   | n/a        |                        |                    |

<div style=\"page-break-after: always\"></div>

|                     | storage site of MCB and/or WCB B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                          |            |            |                       |                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10671 /202305 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                           | 25/01/2024 | 27/03/2024 | SmPC, Annex II and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10671/202305. |
| II/0036             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                   | 14/09/2023 | 27/03/2024 | SmPC and PL           |                                                                                                                                            |
| WS/2541             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation         | 31/08/2023 | n/a        |                       |                                                                                                                                            |
| IB/0034             | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                         | 27/07/2023 | n/a        |                       |                                                                                                                                            |
| II/0033/G           | This was an application for a group of variations. B.I.a.4.e - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS B.I.a.4.e - Change to in-process tests or limits | 20/07/2023 | n/a        |                       |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                     | applied during the manufacture of the AS - Deletion of an in-process test which may have a significant effect on the overall quality of the AS                                                                                                                                                                                                                   |            |            |             |                                                                                                                                                                |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10671 /202205 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                        | 26/01/2023 | 04/04/2023 | SmPC and PL | Please refer to semaglutide PSUSA/10671/202205 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IB/0032/G           | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits | 31/01/2023 | n/a        |             |                                                                                                                                                                |
| II/0030             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                           | 12/01/2023 | n/a        |             |                                                                                                                                                                |
| IB/0031             | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                      | 13/12/2022 | n/a        |             |                                                                                                                                                                |
| WS/2343             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission                                                                                                            | 20/10/2022 | n/a        |             |                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

|                     | of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                       |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                      |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0029             | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                                                                                                                                                 | 12/09/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0026             | B.I.a.3.e - Change in batch size (including batch size ranges) of AS or intermediate - The scale for a biological/immunological AS is increased/decreased without process change (e.g. duplication of line)                                                                                                                                                                                 | 26/07/2022 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                      |
| PSUSA/10671 /202111 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                   | 07/07/2022 | n/a        |             | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                    |
| II/0025             | Update of section 4.8 of the SmPC in order to add 'Hypersensitivity' to the list of adverse drug reactions with frequency uncommon; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 23/06/2022 | 16/12/2022 | SmPC and PL | Hypersensitivity with frequency uncommon has been added to the list of adverse drug reactions. The detection of hypersensitivity is the outcome of a signal of hypersensitivity including rash and urticaria identified via routine signal detection activities examining post-marketing data for oral semaglutide. For more information, please refer to the Summary of Product Characteristics.    |
| WS/2141             | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. Update of section 5.1 of the Ozempic SmPC in order to include information on the use of semaglutide s.c. once weekly vs insulin aspart three times daily, both                                                                                | 07/04/2022 | 16/12/2022 | SmPC        | In a 52-week open-label trial, 1748 subjects with inadequately controlled T2D after a 12-week run-in period on insulin glargine and metformin were randomised to 1:1 to receive either semaglutide once-weekly (0.5 mg or 1.0 mg) or insulin aspart three times daily. The included population had a mean diabetes duration of 13.4 years and a mean HbA1c of 8.6%, with a target HbA1c of 6.5-7.5%. |

<div style=\"page-break-after: always\"></div>

|                     | as add-on to metformin and optimised insulin glargine U100 treatment in subjects with inadequately controlled T2DM; based on the final report from study NN9535-4386 (SUSTAIN-11), listed as a category 3 study in the RMP. This is a 52- week, multi-centre, multinational, open-label, active controlled, two armed, parallel, randomised trial undertaken to investigate the effect on glycaemic control, body weight, safety and health-related quality of life. The SmPC of Rybelsus (semaglutide p.o.) is not impacted. The RMP common for both products has also been updated to version 7.1. C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority   |            |     | Treatment with semaglutide resulted in reduction in HbA1c at week 52 (-1.5% for semaglutide vs. -1.2% for insulin aspart). The number of severe hypoglycaemic episodes in both treatment arms was low (4 episodes with semaglutide vs. 7 episodes with insulin aspart). Mean baseline body weight decreased with semaglutide (-4.1 kg) and increased with insulin aspart (+2.8 kg) and the estimated treatment difference was -6.99 kg (95%CI -7.41 to -6.57) at week 52.   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0024             | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 07/03/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| IB/0022             | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 10/02/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0020             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 27/01/2022 | n/a |                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| PSUSA/10671 /202105 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 13/01/2022 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

| IB/0019/G           | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes   | 09/12/2021   | 16/12/2022   | SmPC, Labelling and PL   |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| IA/0021             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                 | 06/12/2021   | n/a          |                          |                                   |
| PSUSA/10671 /202011 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                    | 08/07/2021   | n/a          |                          | PRAC Recommendation - maintenance |
| IA/0016             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                 | 21/06/2021   | n/a          |                          |                                   |
| IB/0015             | B.I.e.4.b - Changes to an approved change management protocol - Minor changes that do not change the strategy defined in the protocol                                                                                                                                                                                                                                                                                                                        | 17/05/2021   | n/a          |                          |                                   |
| IB/0014/G           | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a                                                                                                                                                                                                                                                                | 22/04/2021   | n/a          |                          |                                   |

<div style=\"page-break-after: always\"></div>

|                     | manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        |                                                                                                                                                            |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012             | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes                                                                                                                                                                                                                                                                                                              | 22/04/2021 | n/a        |                        |                                                                                                                                                            |
| PSUSA/10671 /202005 | Periodic Safety Update EU Single assessment - semaglutide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 28/01/2021 | 28/01/2021 | SmPC and PL            | Please refer to Ozempic PSUSA-10671-202005 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| II/0007             | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 14/01/2021 | n/a        |                        |                                                                                                                                                            |
| IB/0010/G           | This was an application for a group of variations. B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside the range of the currently approved pack sizes B.II.e.5.a.2 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change outside | 13/11/2020 | 18/08/2021 | SmPC, Labelling and PL |                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| II/0006     | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol   | 12/11/2020   | n/a        |      |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------|
| IB/0009     | B.I.e.5.c - Implementation of changes foreseen in an approved change management protocol - For a biological/immunological medicinal product                                                                                                                  | 15/10/2020   | n/a        |      |
| IA/0008     | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                               | 23/09/2020   | n/a        |      |
| IB/0005     | B.I.b.2.c - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure for a reagent, which does not have a significant effect on the overall quality of the AS                                           | 22/09/2020   | n/a        |      |
| IB/0004     | B.I.c.1.a - Change in immediate packaging of the AS - Qualitative and/or quantitative composition                                                                                                                                                            | 22/09/2020   | n/a        |      |
| IB/0002     | B.II.c.z - Change in control of excipients in the Finished Product - Other variation                                                                                                                                                                         | 30/06/2020   | n/a        |      |
| IAIN/0001/G | This was an application for a group of variations. B.II.f.1.a.1 - Stability of FP - Reduction of the shelf life of the finished product - As packaged for sale                                                                                               | 19/05/2020   | 18/08/2021 | SmPC |

<div style=\"page-break-after: always\"></div>

| B.II.f.1.e - Stability of FP - Change to an approved   |          |
|--------------------------------------------------------|----------|
| stability                                              | protocol |